iRadimed Lowers FY2026 Adj EPS Guidance from $2.09-$2.24 to $2.07-$2.11 vs $2.11 Est; Narrows FY2026 Sales Guidance from $91.000M-$96.000M to $91.600M-$93.100M vs $92.133M Est
Benzinga Newsdesk 1 day ago
NewsGuidance
iRadimed (NASDAQ:IRMD) lowers FY2026 Adj EPS guidance from $2.09-$2.24 to $2.07-$2.11 vs $2.11 analyst estimate. Narrows FY2026 sales outlook from $91.000 million-$96.000 million to $91.600 million-$93.100 million vs
iRadimed (NASDAQ:IRMD) lowers FY2026 Adj EPS guidance from $2.09-$2.24 to $2.07-$2.11 vs $2.11 analyst estimate. Narrows FY2026 sales outlook from $91.000 million-$96.000 million to $91.600 million-$93.100 million vs $92.133 million estimate.